Skip to main content

Table 1 Characteristics of 216 patients with primary MDS

From: Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes

Variable

All patients

Elevated PMMBM group

Normal group

P-value

Age, years median (range)

61 (16–90)

62 (24–83)

61 (16–90)

0.971

Male/Female, n

117/99

23/13

94/86

0.200

BM blast, % median (range)

3.5 (0–19.5)

8.8 (0–19.5)

3.0 (0–19.5)

< 0.0001

PMMBM, % median (range)

3.0 (0–24.0)

7.5 (6.5–24.0)

3.0 (0–6.0)

< 0.0001

Peripheral Blood

 NE, × 109/L median (range)

1.2 (0–7.4)

0.8 (0–6.6)

1.2 (0.1–7.4)

0.022

 HB, g/dl median (range)

7.7 (2.2–14.2)

8.6 (2.9–13.4)

7.6 (2.2–14.2)

0.463

 PLT, ×109/L median (range)

51.5 (2.0–340.0)

42.0 (6.0–332.0)

55.0 (2.0–340.0)

0.143

 Monocytes, ×109/L median (range)

0.2 (0–0.8)

0.2 (0–0.7)

0.2 (0–0.8)

0.102

 Monocytes, % median (range)

7.1 (0.4–39.0)

10.1 (0.7–27.2)

6.3 (0.4–39.0)

< 0.0001

 SF, μg/L median (range)

304.4 (5.5–2612.0)

242.0 (9.5–1447.6)

307.0 (5.5–2612.0)

0.749

 β2-MG, mg/L median (range)

1.8 (0–12.6)

2.2 (0.4–5.5)

1.8 (0–12.6)

0.058

 LDH, IU/L median (range)

207.0 (54.0–1083.0)

215.0 (123.0–616.0)

203.5 (54.0–1083.0)

0.373

 Cytogenetic abnormalities, % (n/n)

45.1 (83/184)

50.0 (15/30)

44.2 (68/154)

0.556

WHO classification

   

0.005

 MDS-SLD, % (n/n)

13.4 (29/216)

8.3 (3/36)

14.4 (26/180)

 

 MDS-MLD, % (n/n)

27.8 (60/216)

14.0 (5/36)

30.6 (55/180)

 

 MDS-RS, % (n/n)

6.0 (13/216)

0 (0/36)

7.2 (13/180)

 

 MDS-EB1, % (n/n)

21.8 (47/216)

22.2 (8/36)

21.7 (39/180)

 

 MDS-EB2, % (n/n)

22.2 (48/216)

47.2 (17/36)

17.2 (31/180)

 

 MDS-del(5q), % (n/n)

0.5 (1/216)

0 (0/36)

0.6 (1/180)

 

 MDS-U, % (n/n)

8.3 (18/216)

8.3 (3/36)

8.3 (15/180)

 

IPSS-R cytogenetic

risk

   

0.756

 Very good, % (n/n)

0.5 (1/185)

0 (0/30)

0.5 (1/155)

 

 Good, % (n/n)

66.5 (123/185)

56.7 (17/30)

66.5 (106/155)

 

 Intermediate, %(n/n)

20.0 (37/185)

26.7 (8/30)

20.0 (29/155)

 

 Poor, % (n/n)

2.7 (5/185)

3.3 (1/30)

2.7 (4/155)

 

 Very poor, % (n/n)

10.3 (19/185)

13.3 (4/30)

10.3 (15/155)

 

IPSS-R risk

   

0.025

 Very low, % (n/n)

7.6 (14/185)

0 (0/30)

9.0 (14/155)

 

 Low, % (n/n)

22.2 (41/185)

6.6 (2/30)

25.2 (39/155)

 

 Intermediate, % (n/n)

34.6 (64/185)

36.7 (11/30)

34.2 (53/155)

 

 High, % (n/n)

17.8 (33/185)

30.0 (9/30)

15.5 (24/155)

 

 Very high, % (n/n)

17.8 (33/185)

26.7 (8/30)

16.1 (25/155)

 

 Gene mutation, % (n/n)

68.8 (55/80)

77.8 (7/9)

67.6 (48/71)

0.811

 Leukemia transformation, % (n/n)

13.0 (28/216)

22.2 (8/36)

11.1 (20/180)

0.070

  1. Abbreviations: BM bone marrow, PMMBM the percentage of mature monocyte in bone marrow, NE neutrophil, HB hemoglobin, PLT platelet, LDH lactate dehydrogenase, MDS-SLD MDS with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS with ring sideroblasts, MDS-EB MDS with excess blasts, MDS-U unclassifiable, IPSS-R Revised International Prognostic Scoring System
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us